Mometasonfuroat Al (Mometasone Furoate Ph. Eur.)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. This interaction modifies gene expression, suppressing the release of inflammatory mediators such as cytokines and prostaglandins, which reduces swelling and irritation of the nasal mucosa.

The specific dosing regimen for Mometasonfuroat Al is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Patients should follow the prescriber’s instructions and the product label.

Safety data for mometasone furoate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a favorable safety profile when used as directed. Compared with older agents such as beclomethasone, it offers once‑daily dosing and a lower risk of systemic absorption, making it a preferred option for many clinicians.

Store Mometasonfuroat Al at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Mometasonfuroat Al is administered as a nasal spray. The patient should gently blow the nose, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The same procedure is repeated in the other nostril if required.

Serious risks, although rare, include fungal infections of the nasal mucosa, severe nosebleeds, adrenal suppression, cataracts or glaucoma, and anaphylactic reactions. Patients should seek immediate medical attention if they experience unusual bleeding, visual changes or signs of an allergic reaction.

Mometasonfuroat Al should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated fungal infections of the nasal passages and should be used with caution after recent nasal surgery.